Rizonib Capsule 250 mg contains Crizotinib, an oral targeted therapy used in the treatment of specific types of non-small cell lung cancer (NSCLC) that harbor genetic mutations such as ALK (anaplastic lymphoma kinase) or ROS1 rearrangements. Crizotinib is a tyrosine kinase inhibitor that blocks abnormal signaling pathways in cancer cells, thereby slowing tumor growth and progression.

Rizonib offers a precision medicine approach to lung cancer, targeting the molecular drivers of malignancy. It is particularly beneficial for patients who have shown disease progression or are unsuitable for conventional chemotherapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Crizotinib 250 mg per capsule

Mechanism of Action

Crizotinib selectively inhibits multiple receptor tyrosine kinases, including ALK, ROS1, and MET. These kinases are involved in cellular growth and proliferation. By blocking their activity, Crizotinib:

• Interrupts cancer cell signaling

• Reduces tumor cell growth

• Promotes cancer cell death (apoptosis)

• Slows disease progression

This targeted mechanism allows for effective therapy with relatively fewer systemic side effects compared to traditional cytotoxic chemotherapy.

Indications

Rizonib Capsule 250 mg is indicated for:

• ALK-positive non-small cell lung cancer (NSCLC)

• ROS1-positive NSCLC

• Advanced or metastatic NSCLC with genetic mutations confirmed by molecular testing

Treatment should be initiated and monitored by an oncologist experienced in managing targeted cancer therapies.

Dosage and Administration

The recommended adult dose is usually 250 mg orally twice daily, approximately 12 hours apart. Capsules should be swallowed whole with water and can be taken with or without food.

Patients should continue therapy as long as clinical benefit is observed or until unacceptable toxicity occurs. Dose modifications may be required for adverse reactions or liver impairment.

Regular monitoring of liver function, blood counts, and cardiac status is essential during treatment. Baseline ECG and periodic assessments are recommended to detect potential QT interval prolongation.

Benefits

• Specifically targets genetic mutations driving NSCLC

• Reduces tumor progression and metastatic spread

• Provides an oral, convenient treatment option

• Improves survival and quality of life in selected patients

• May be used in patients unsuitable for conventional chemotherapy

Precautions

Rizonib should be used with caution in patients with:

• Liver or kidney impairment

• Heart rhythm disorders

• History of gastrointestinal perforation or bleeding

Patients should avoid grapefruit and grapefruit juice, which may interfere with drug metabolism. Women of childbearing potential should use effective contraception during treatment, and breastfeeding is not recommended.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Nausea, vomiting, and diarrhea

• Vision disturbances (blurred vision, visual changes)

• Fatigue and decreased appetite

• Swelling or edema

• Constipation or mild liver enzyme elevation

Serious but less common effects include liver toxicity, cardiac arrhythmias, pneumonitis, and severe gastrointestinal issues. Any new or severe symptoms should prompt immediate medical attention.

Storage

Store capsules below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use capsules that are damaged or expired.

Rizonib Capsule 250 mg provides targeted therapy for ALK- or ROS1-positive NSCLC, offering effective disease management and improved patient outcomes under specialized oncology supervision.